Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 4
1(25.0%)
4Total
Phase 2(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06212336Phase 2Recruiting

ISTH/ANRS 0409s INTEGRATE Lassa Fever Study

Role: collaborator

NCT03991013Phase 2Completed

Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial

Role: collaborator

NCT05453253Phase 4Unknown

Immune Response to a Delayed Second Dose of Oral Cholera Vaccine

Role: collaborator

NCT02342171Phase 2Completed

Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea

Role: collaborator

All 4 trials loaded